Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 December;52(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 December;52(4):369-77

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  MIBG IN DIAGNOSIS AND THERAPY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 December;52(4):369-77

Copyright © 2008 EDIZIONI MINERVA MEDICA

language: English

Cardiac 123I-MIBG scintigraphy in heart failure

Agostini D. 1, Verberne H. J. 2, Hamon M. 1, Jacobson A. F. 3, Manrique A. 1

1 CHU Cote de Nacre, Caen, France 2 Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands 3 GE Healthcare, Princeton, NJ, USA


PDF


This review focuses on myocardial [123I]mIBG imaging in patients with cardiomyopathy and heart failure (HF). In particular, the potential role of myocardial 123I-mIBG scintigraphy in the prediction of potentially fatal arrhythmic events is described. A growing body of evidence supports the use of cardiac sympathetic innervation imaging, specifically using 123I-mIBG, to risk stratify patients with HF. Cardiac sympathetic imaging can help to improve understanding of the mechanisms responsible for increased sympathetic activity in HF, and how sympathetic over-activity exerts its deleterious actions. Eventually, this may result in more effective therapies and, thereby, better outcome for these patients. Assessment of cardiac sympathetic activity could also contribute to a more appropriate selection of individual patients for implantable cardioverter-defibrillators (ICD).

top of page